Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

King Abdulaziz University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Periodontal Diseases; Type 2 Diabetes

Treatments: Drug: Group I; Drug: Group III; Drug: Group II

Study type: Interventional

Funder types: Other

Identifiers

NCT06199440

121-06-23

Details and patient eligibility

About

The aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (NSPT), compared with NSPT alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy

Enrollment: 15 patients

Sex: All

Ages: 25 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients were clinically diagnosed as having at least three site with CAL ≥ 5mm; moderate to advanced chronic periodontitis according to the criteria of American Academy of Periodontology.

• Free from any other systemic conditions that affect the periodontium except for Diabetes mellitus type II.
• No periodontal therapy, systemic antibiotics or non-steroidal anti-inflammatory agents during the preceding 6 months.
• Non-smokers.
• Non-pregnant.

Exclusion criteria

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

15 participants in 3 patient groups

Group I

Active Comparator group

Description:

Chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

Treatment:

Drug: Group I

Group II

Experimental group

Description:

Received azithromycin dosage is 250 mg/day for 5 days, after an initial dose of 500 mg one hour before NSPT

Treatment:

Drug: Group II

Group III

Experimental group

Description:

Consisted of 5 type 2 Diabetes Mellitus patients with periodontitis who were received doxycycline 20mg twice/day.

Treatment:

Drug: Group III